stella
beta
Alpha Radiation Emitters Device (DaRT) in Combination With Check Point Inhibitor for the Treatment of Recurrent Unresectable or mHNSCC — Stella
Home
/
Head and Neck Squamous Cell Carcinoma
/
Alpha Radiation Emitters Device (DaRT) in Combination With Check Point Inhibitor for the Treatment of Recurrent Unresectable or mHNSCC
View on ClinicalTrials.gov
Recruiting
Back to Head and Neck Squamous Cell Carcinoma trials
Alpha Radiation Emitters Device (DaRT) in Combination With Check Point Inhibitor for the Treatment of Recurrent Unresectable or mHNSCC
Not a traditional drug trial — this study doesn't follow the standard phase structure.
Trial locations
(3 sites)
Israel
Sharett institute, Hadassah University Hospital - Ein-Kerem, Jerusalem
Sheba Medical Center, Ramat Gan
Tel-Aviv Medical Center, Tel Aviv